MedTrace Logo

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy

NCT04398992 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-02-09

No results posted yet for this study

Summary

Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS.

Twenty Chinese cardiovascular centers have collaborated to create a multicenter observational registry (named Chinese registry of Additive Anti-inflammatory Action for Aortopathy \& Arteriopathy \[5A\]), with consecutive enrollment of adult patients who underwent surgery for AAS that was started on Jan 1, 2016 and will be ended on December 31, 2040. Specially, the impact of inflammation and anti-inflammatory strategies on the early and late adverse events are investigated. Primary outcomes are severe systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), Sequential Organ Failure Assessment (SOFA) scores at 7 days following this current surgery. Secondary outcomes are SISR, 30-day mortality, operative mortality, hospital mortality, new-onset stroke, acute kidney injury, surgical site infection, reoperation for bleeding, blood transfusion and length of stay in the intensive care unit.

Conditions

  • Acute Aortic Syndrome

Interventions

OTHER

observation

Data were collected by a designed form. Statistic software was used to analyze clinical data.

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    collaborator OTHER

  • Nanjing Medical University

    lead OTHER

Principal Investigators

  • Hong-jia Zhang, MD · Beijing Anzhen Hospital

  • Hong Liu · Nanjing Medical University

  • Si-chong Qian · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398992 on ClinicalTrials.gov